Binding Site Sells Autoimmune Business to Werfen

Financial details of the transaction were not disclosed.

The Binding Site autoimmune diagnostics side of the business develops, manufactures, and distributes a range of assays and reagents used in hospital labs worldwide, to help diagnose and monitor the treatment of autoimmune diseases. These include rheumatoid arthritis, antiphospholipid syndrome, vasculitis, and celiac disease.

Binding Site will continue to manufacture autoimmune products on behalf of the Werfen Group, enabling Werfen to continue servicing the Binding Site autoimmune business. The protein business of Binding Site includes Freelite and Hevylite, which will be unaffected by the acquisition.

Paul Duncan, CEO of The Binding Site said, "The Binding Site has built a strong niche in the autoimmune sector. We are confident that a company of the caliber of Werfen will be well placed to continue to deliver the level of quality and service that our customers have come to expect and we look forward to working closely with Werfen and our customers to ensure a smooth transition over the coming months."

Werfen will continue investing in the research and development of early biomarkers, instrumentation and software, which could help in the early diagnosis of diseases.

Related Links:
Binding Site
Werfen Group